Autologous stem cell transplantation (ASCT) has yielded favourable outcomes in a high-risk cohort of patients with relapsed/refractory Hodgkin lymphoma (HL) who had previously been treated with anti-PD-1 therapy. The results were seen even among patients who were previously chemorefractory, according to US researchers. “Historically, patients with chemorefractory R/R HL or those who require multiple salvage ...
ASCT after PD-1 blockade effective in refractory Hodgkin lymphoma
By Dave Levitan
25 Mar 2021